G-Proteins are part of a superfamily of proteins that activate receptors or turn receptors off. They hold the keys to the safe. They are the newest "smart bombs" for human genetic disorders such as rosacea.

I published about the importance of G-Proteins in my book 11 years ago and followed up with several studies and publications the last 5 years on this cutting-edge approach. This was part of my primary training as a Neuro-Vascular Physiologist. G-Protein targetting is smart, efficient and effective. Just review the latest treatments that selectively target G-Proteins:

(1) SansRosa is a selective G-Protein modulator - primarily through alpha adrenergic receptor activation

(2) Arazine and Sig990 are both selective G-Protein Modulators - focused on blocking G-proteins responsible for inflammation

(3) Vicept Therapeutics V-101 is a selective G-Protein Modulator - primarily through alpha adrenergic receptor activation

(4) Phenylephrine (the patent held by Dr. Bitter and myself) is a selective G-Protein Modulator - primarily through alpha adrenergic receptor activation

These G-Protein Modulators are our best chance for attaining remission and near-cures. These are the products to watch.

Just so you gently ease into the complicated lingo, it would be wise to read up on G-Proteins in the Wikipedia

G protein-coupled receptor - Wikipedia, the free encyclopedia

_

__________________
_

Best,
Geoffrey

Dr. Geoffrey Nase
Ph.D: Neuro-Vascular Physiologist

Email: drnase1000@hotmail.com
Bibliography: http://drnase.com

All posts are for informational purposes only. Please visit our Home Page to view our Medical Disclaimer.

Sorry folks. I just read the wikipedia page link on G-proteins. There is nothing gentle about it. I just threw you into the deep end of the pool with Great White Sharks and a piece of duct tape to defend yourself with... I'll find a better example. Some of the animations are very good.

_

__________________
_

Best,
Geoffrey

Dr. Geoffrey Nase
Ph.D: Neuro-Vascular Physiologist

Email: drnase1000@hotmail.com
Bibliography: http://drnase.com

All posts are for informational purposes only. Please visit our Home Page to view our Medical Disclaimer.

Newest thing I've heard. Could this help stop inflammation??

DermaWhey, 400 mg, 60 capsules

Interesting Chanel 77!

I use whey protein isolates for weight lifting, but this seems to be a different fraction with skin properties instead of muscle building properties. I like LifeExtension as they are one of the best researched and most medically up to date manufacturers that I have come across.

I don't know if it should help as I would need more specifics on the peptides and immunoglobulins to even make an educated guess.

Try it out and give us a report in three months (or earlier if it helps).

Good luck.

_

__________________
_

Best,
Geoffrey

Dr. Geoffrey Nase
Ph.D: Neuro-Vascular Physiologist

Email: drnase1000@hotmail.com
Bibliography: http://drnase.com

All posts are for informational purposes only. Please visit our Home Page to view our Medical Disclaimer.

Dr Nase,,,

Can you tell us more on your workout routine!

__________________
Doug

Vivept V101 just finished PhaseII
Vicept Therapeutics Announces Positive Phase II Data of V-101 for the Treatment of Type I Rosacea (Erythematotelangiectatic Rosacea) - News Press Release | PharmiWeb.com

Vicept Therapeutics Announces Positive Phase II Data of V-101 for the Treatment of Type I Rosacea (Erythematotelangiectatic Rosacea)
Vicept Therapeutics Inc.Posted on:10 Jan 11
• More Vicept Therapeutics Inc. press releases
Vicept Therapeutics, Inc. announced today positive study results from a Phase II clinical trial evaluating the dose-response relationship of four concentrations of V-101 cream, a topical cream for the treatment of Type I Rosacea (Erythematotelangiectatic Rosacea). The results demonstrated a statistically significant (p=0.0006) improvement in the primary end point, which was a reduction in facial erythema, over an eight hour period in patients with erythematotelangiectatic rosacea (ETR), versus placebo. Further, V-101 demonstrated a safety profile similar to placebo cream and no evidence of “rebound” or tachyphylaxis was observed.
“These positive data showed that V-101 significantly reduced the redness associated with Type I rosacea (ETR) and demonstrated a favorable side effect profile, further confirming its potential to be the first effective topically applied therapy directed specifically toward the erythema of rosacea,” said Dr. Neal Walker, President and Chief Executive Officer of Vicept. “This is a major milestone for the Company and we are poised and committed to continue the advancement of the V-101 development program.”
Study V-101-ROSE-202 is a prospectively randomized, multi-centered, double-blinded, placebo-controlled, Phase II clinical trial designed to evaluate the dose-response relationship of four concentrations of V-101 cream vs. vehicle (placebo) for the treatment of the erythema associated with rosacea. A total of 183 patients with moderate to severe erythema participated at seven investigational centers across the United States. Patients were divided among five groups and self-administered one of four concentrations of V-101 cream or vehicle (placebo) cream once daily for 28 days. The study also demonstrated that V-101 cream was well-tolerated in these patients, a population of patients with facial skin that is highly sensitive to topical preparations. The safety profile of all the active preparations was similar to that of placebo.
About Rosacea
Rosacea is a common, chronic cutaneous disorder that affects over 15 million Americans and over 45 million people worldwide. Erythematotelenagietic rosacea (ETR), Type I, is the most commonly encountered subtype, and is most characterized by frequent episodes of transient facial erythema (flushing) and non-transient, or persistent, erythema. It may also be accompanied by facial edema, burning, or stinging, and sensitivity of the skin and intolerance to topically applied products is common. Rosacea remains a disorder of uncertain etiology and pathogenesis, though the flushing and erythema of ETR are theorized to arise from an abnormal response of the cutaneous blood vessels of the face to neurological, hormonal, thermal, topical, or other stimuli, resulting in an abnormal dilation of facial blood vessels. There is currently no approved topical therapy for the treatment of ETR (erythematotelangiectatic) rosacea.
About Vicept Therapeutics
Vicept Therapeutics, Inc. is a is a privately held specialty pharmaceutical company with a mission to develop the first effective topically applied therapy directed toward the erythema of rosacea and other disorders characterized by redness and or flushing of the skin. The Company is also pursuing the development of topical agents for the treatment and prevention of a number of medical and cosmetic indications including bruising of the skin. The Company is based in Malvern, Pennsylvania and more information can be found by visiting the Company’s website at Vicept Therapeutics Incorporated - biopharmaceutical, dermatology market, rosacea
Business Wire
Press release distribution, EDGAR filing, XBRL, regulatory filings | Business Wire

Last updated on: 10/01/2011 14:00:06

Read more: Vicept Therapeutics Announces Positive Phase II Data of V-101 for the Treatment of Type I Rosacea (Erythematotelangiectatic Rosacea) - News Press Release | PharmiWeb.com

Barbara